Yang P.-C.JHE-CYUAN GUOMIN-SHU HSIEHCHIA-CHI LINCHIH-HUNG HSU2020-04-282020-04-2820181556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042449118&doi=10.1016%2fj.jtho.2017.10.022&partnerID=40&md5=c1967c4c749456b3aa12186d94bf8ba0https://scholars.lib.ntu.edu.tw/handle/123456789/487263[SDGs]SDG3cisplatin; cyclophosphamide; doxorubicin; fluorouracil; folinic acid; gemcitabine; mismatch repair protein PMS2; MutL protein homolog 1; nivolumab; paclitaxel; programmed death 1 ligand 1; protein MSH6; tumor marker; monoclonal antibody; nivolumab; pembrolizumab; adult; cancer chemotherapy; cancer palliative therapy; cancer radiotherapy; cancer staging; case report; clinical article; computer assisted tomography; dyspnea; female; heart metastasis; hemoptysis; human; human cell; human tissue; immunohistochemistry; Letter; liver metastasis; lung gas exchange; lung hilus; lung metastasis; lymph node metastasis; lymphadenopathy; mediastinum metastasis; middle aged; multiple cycle treatment; pleura metastasis; priority journal; protein expression; repeated drug dose; salvage therapy; supraclavicular lymph node; thymus cancer; treatment response; lung tumor; salvage therapy; thymoma; tumor recurrence; Antibodies, Monoclonal, Humanized; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Salvage Therapy; Thymomaletter10.1016/j.jtho.2017.10.022294720562-s2.0-85042449118